Uniogen specializes in advanced diagnostics, particularly in the field of cancer detection. Their innovative glycovariant immunoassay technology utilizes nanoparticles coated with carbohydrate group-specific binders, which enhances the sensitivity and specificity of cancer diagnostics compared to traditional methods. The company is actively developing a proprietary test aimed at the early detection of ovarian cancer and holds patents for various cancer detection technologies. This focus on improving diagnostic accuracy is further supported by their state-of-the-art manufacturing capabilities, which include modular microplate readers equipped with multiple measuring technologies such as upconverting nanoparticles, time-resolved fluorometry, fluorescence, luminescence, and absorbance.

In addition to their diagnostic technologies, Uniogen offers a range of ready-to-use reagents and individualized assay development services tailored for high-quality in vitro diagnostics (IVD) immunoassays and antibody tests. Their GenomEra® CDX system provides a cost-effective solution for routine molecular diagnostics, including CE-marked tests for infectious agents like SARS-CoV-2. Uniogen's commitment to advancing cancer diagnostics is exemplified by their ongoing research and development efforts, particularly in enhancing the detection capabilities for challenging cases, such as early-stage ovarian cancer, through their innovative assays.

Finland

Three Finnish life science experts have joined forces to form Uniogen, a global pioneer in diagnostic solutions and point-of-care testing. Building on the strong track record of Abacus Diagnostica, Kaivogen and Labrox,

Uniogen

Company Details